Brookline Capital Management Predicts Oncobiologics Q1 Earnings

Oncobiologics, Inc. (NASDAQ:OTLK) – Equities researchers at Brookline Capital Management issued their Q1 2026 earnings per share estimates for Oncobiologics in a research note issued to investors on Friday, January 2nd. Brookline Capital Management analyst K. Dolliver anticipates that the company will post earnings per share of ($0.16) for the quarter. The consensus estimate for Oncobiologics’ current full-year earnings is ($2.27) per share. Brookline Capital Management also issued estimates for Oncobiologics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.20) EPS and Q4 2026 earnings at ($0.22) EPS.

Oncobiologics (NASDAQ:OTLK) last released its quarterly earnings data on Friday, December 19th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. The business had revenue of $4.65 million during the quarter, compared to analysts’ expectations of $5.85 million.

OTLK has been the topic of several other research reports. Wall Street Zen cut Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright restated a “neutral” rating on shares of Oncobiologics in a research note on Tuesday, September 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncobiologics in a research report on Monday, December 29th. Finally, Ascendiant Capital Markets lifted their target price on Oncobiologics from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $7.00.

Oncobiologics Stock Performance

NASDAQ:OTLK opened at $0.66 on Monday. The firm has a 50-day simple moving average of $1.70 and a 200-day simple moving average of $1.66. Oncobiologics has a one year low of $0.60 and a one year high of $3.39. The firm has a market cap of $42.31 million, a P/E ratio of -0.43 and a beta of 0.17.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in shares of Oncobiologics by 865.2% during the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares during the period. AQR Capital Management LLC increased its holdings in Oncobiologics by 42.7% in the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after buying an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in Oncobiologics by 74.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after buying an additional 44,063 shares during the period. 11.20% of the stock is owned by institutional investors and hedge funds.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.